Browsing Tag
Johnson & Johnson
103 posts
Can Protagonist’s icotrokinra become the first oral IL-23 therapy to rival biologics in ulcerative colitis?
Positive Phase 2b data for Protagonist Therapeutics’ oral IL-23R inhibitor icotrokinra show strong efficacy and safety in ulcerative colitis; learn what’s next for Phase 3.
Wall Street reacts as Johnson & Johnson circles Protagonist Therapeutics in a potential multibillion-dollar buyout
Explore how Johnson & Johnson’s bid to acquire Protagonist Therapeutics could reshape its immunology and hematology pipeline—details inside.
Johnson & Johnson (NYSE: JNJ) gains FDA approval to expand SIMPONI into pediatric ulcerative colitis
FDA approves SIMPONI (golimumab) for children ≥15 kg with ulcerative colitis, expanding Johnson & Johnson’s immunology portfolio. Learn what it means for patients.
Inside Johnson & Johnson’s $966m talc verdict: how one case could reshape its future battles
Find out how Johnson & Johnson’s $966 million talc cancer verdict could reshape its litigation strategy, investor sentiment, and brand credibility.
Johnson & Johnson wins FDA approval for Tremfya in pediatric psoriasis and psoriatic arthritis
Johnson & Johnson wins FDA approval for Tremfya in pediatric psoriasis and psoriatic arthritis, extending its immunology lead and boosting growth prospects.
Can immune-based doublets push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can immune-based doublets like TECVAYLI and DARZALEX FASPRO push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
AusperBio raises $63mn series B2 round to advance AHB-137 and expand global hepatitis B
AusperBio raises $63M Series B2 funding to advance AHB-137 pivotal trials, expand its Med-Oligo platform, and reshape the hepatitis B cure race.
Can Johnson & Johnson’s TECVAYLI and DARZALEX FASPRO regimen redefine first-line multiple myeloma treatment?
Johnson & Johnson’s TECVAYLI + DARZALEX FASPRO combo hit 100% MRD negativity in new myeloma trial. Can this immune-based regimen redefine frontline care?
Johnson & Johnson (NYSE: JNJ) wins key CHMP backing for nipocalimab in gMG—could this reshape Europe’s autoimmune treatment market?
Johnson & Johnson’s nipocalimab wins CHMP backing for gMG, setting stage for potential EU approval in adults and adolescents. Learn what this means for patients.
Why Henlius Biotech’s HLX43 deal talks with Johnson & Johnson and Roche are shaking up global oncology
Henlius Biotech is negotiating with Johnson & Johnson and Roche on HLX43 rights. Learn how this deal could reshape oncology licensing and investor sentiment.